Evaluate EGFR Mutation Status and Impact Factors in North China

Non-Small Cell Lung Cancer Clinical Trial

Official title:

A Retrospective Study on Real-world EGFR Mutation Testing Practice Status and Impact Factors in Patients With Advanced NSCLC in North China

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02620657
• Other study ID #: 11224
• Status: Completed
• Start date: December 2015
• Est. completion date: November 8, 2017

Study information

• Verified date: August 2019
• Source: Guangdong Association of Clinical Trials
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Approximately 3000 advanced NSCLC patients, who fulfil the inclusion/exclusion criteria, will be recruited by 30 sites in North China.

Description:

Approximately 3000 advanced NSCLC patients will be recruited , and the medical information of recruited patients must be recorded in the hospital electronic system from Jan 1st 2014 to Dec 31st 2014 .The study will focus on the EGFR testing rate in adenocarcinoma patients，so the collecting data for non-adenocarcinoma patients will be controlled in less than 10% for each site.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2809
• Est. completion date: November 8, 2017
• Est. primary completion date: November 8, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Histological or cytological confirmed NSCLC;

• Patients were diagnosed with advanced NSCLC from Jan 1st 2014 to Dec 31st 2014;

• Researchers should collect the records of consecutive NSCLC patients in each site.

Exclusion Criteria:

• Any patients without NSCLC diagnosis;

• Any patients which were diagnosed with advanced NSCLC before Jan 1st 2014 or after Dec 31st 2014.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Non-Small Cell Lung Cancer

Intervention

Other:
• Non interventional study
Non interventional study

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
ying cheng

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To investigate the proportion of advanced NSCLC patients who performed EGFR mutation test		2014.01.01-2014.12.31